J goodtech
M Bio Technology Inc.
M Bio Technology Inc.

We are a biotechnology venture company founded with patented techniques based on the mycoplasma lipid antigen.

We are attempting to overcome mycoplasma infection leading to chronic or intractable disease. This is done by putting techniques based on the mycoplasma lipid antigen, which the founder has studied, to practical use for development of a vaccine and diagnostic agent. The lipid antigen is a patented substance, and has already been registered in Japan and abroad. The diagnostic agent has been placed on the Japanese market and can be internationally ordered. We have already applied for an international patent for the vaccine, and we are now in negotiations to prepare the vaccine for the Japanese, US, and European markets.

  • Business Outline

    We are attempting to overcome mycoplasma infection by establishing innovative methods for its diagnosis, prevention, and treatment. This is done by putting the results of studies on the mycoplasma lipid antigen to practical use. Mycoplasma infection can lead to pneumonia and also asthma, arthritis, nephritis, meningitis, encephalitis, vasculitis, dermatitis, and so on. It causes various symptoms, which makes it difficult to discriminate mycoplasma infection from rheumatic disease, nervous system disease, and the like. We are conducting drug discovery research in an attempt to develop a vaccine and antibody preparation using techniques based on the mycoplasma lipid antigen. We are also attempting to overcome diseases related to the microbial lipid antigen by introducing techniques to analyze the lipid antigen into clinical diagnosis and treatment. We have a foundational concept of open innovation and global development, and hope for joint development, business collaboration, and financial information and support.

  • Product Strength

    Mycoplasma infection causes various symptoms. It is impossible to definitely diagnose this infection with any existing diagnostic agents. Our techniques are based on the mycoplasma lipid antigen, and can be applied to the development of a safe, highly effective vaccine. An international patent application has already been filed and is in the request for examination stage. It is easy to control the vaccine quality. This is because a lipid antigen that is the same as the natural product is chemically synthesized as a vaccine raw material and no culturing is conducted. The vaccine is safe and has stable effects, because it contains no impurities or adjuvants (artificial products augmenting immune response). For the same reasons, the diagnostic agent produced with this lipid antigen is also excellent in quality.

  • Company Strength

    Our company is a biotechnology-related venture company founded with the patent techniques of Kazuhiro Matsuda (et al.) based on the mycoplasma lipid antigen. Representative director Kazuhiro Matsuda is a doctor. He obtained his doctorate from Yamaguchi University Graduate School of Medicine and served as an assistant in the Department of Microbiology, Faculty of Medicine, Tokyo Medical and Dental University. He then studied at Johns Hopkins University (US) and the National Institutes of Health (US). Dr. Matsuda has engaged in collaborations with many universities and research institutions, and is positioned at the core of our technology. The manager of the clinical development department, Yukie Matsuda, is a dermatologist. We are a slim company with expertise in medical care, and we have a unified process from basic research to clinical applications.

  • Company Structure

    We will make international contracts and engage in international trade in the future, so we are consulting an external consultant familiar with international contracts. Representative director Kazuhiro Matsuda is a doctor. He obtained his doctorate from Yamaguchi University Graduate School of Medicine and served as an assistant in the Department of Microbiology, Faculty of Medicine, Tokyo Medical and Dental University. He then studied at Johns Hopkins University (US) and the National Institutes of Health (US). Dr. Matsuda has engaged in collaborations with many universities and research institutions, and is positioned at the core of our technology.

Product List
image
image
image
Message from President
Kazuhiro Matsuda

We are putting techniques based on the mycoplasma lipid antigen to practical use for the development of a vaccine and diagnostic agent. Founder Kazuhiro Matsuda has been studying these techniques since before the foundation of the company. Our aim is to overcome mycoplasma infection leading to chronic or intractable disease. The lipid antigen is a patented substance and has already been registered in Japan and overseas. The diagnostic agent produced with this lipid antigen for research and examination has been placed on the Japanese market. We have prepared a system for receiving international orders. Moreover, we have developed a mycoplasma infection vaccine, for which we have filed an international patent application. We are now negotiating with authorities, companies, and investors to prepare the vaccine for the Japanese, US, and European markets.

Certificate

Awards and Media

Housing grant in the second half of FY 2012 by Himawari High-Tech Venture Development Foundation (Public Interest Incorporated Foundation).

Basic information
Company name M Bio Technology Inc.
Representative name Kazuhiro Matsuda
Representative position name President
Address ZIP Cpde 158-0081
2-1-3-1103, Fukazawa   Setagaya-ku   Tokyo
Phone number 080-3498-7605
Fax number 03-3705-5230
Foundation date 2005
Capital 186,210,000 (JPY)
Employee number 2
URL http://mbiotech.org/
Other sites Mycoplasma Infectious Diseases Research Center
Transaction performance (domestic) We have already received orders for the mycoplasma lipid antigen/antibody test from a number of clinics and university hospitals through our analysis center.
Transaction performance (overseas) We are now negotiating with overseas companies, universities, and so on.
Event
Bio Japan 2013; BIO Europe Spring 2013; Bio Japan 2014 (scheduled); Biotech Showcase 2014; BIO Europe Spring 2014 (scheduled).